ArticleAlzheimer's research & therapy2022
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration.
Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Comparing Cerebellar tDCS and Cerebellar tACS in Neurodegenerative Ataxias Using Wearable Sensors: A Randomized, Double-Blind, Sham-Controlled, Triple-Crossover Trial.Cerebellum (London, England) · 2024Trial
- Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid.Annals of clinical and translational neurology · 2026Article
- Temporal order of clinical, imaging, and biomarker changes in frontotemporal lobar degeneration-associated syndromes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Review
- The Association Between Serum Copper Levels and Proteomics in Mild Cognitive Impairment.Nutrients · 2026Article
- Epilepsy and EEG abnormalities in neurodegenerative dementias: toward a system epilepsy framework.Frontiers in aging neuroscience · 2026Review
- Classification of AD and bvFTD using neuropsychological and neuropsychiatric variables: a machine learning study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Physical and biopsychosocial frailty, cognitive phenotypes, and plasma biomarkers for Alzheimer's disease in Chinese older adults: A population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease.Brain : a journal of neurology · 2025Article
- Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders.Molecular neurodegeneration · 2025Article
- Development of Neurodegenerative Disease Diagnosis and Monitoring from Traditional to Digital Biomarkers.Biosensors · 2025Review
- Biofluid biomarkers for Alzheimer's disease: past, present, and future.Medical review (2021) · 2024Review
- Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.International journal of molecular sciences · 2024Review
- SIMOA Diagnostics on Alzheimer's Disease and Frontotemporal Dementia.Biomedicines · 2024Article
- Sex Differences in the Severity and Progression of Neuropsychiatric Symptoms Across Different Dementia Types.Neurology. Clinical practice · 2024Article
- Plasma biomarkers increase diagnostic confidence in patients with Alzheimer's disease or frontotemporal lobar degeneration.Alzheimer's research & therapy · 2024Article
- Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.Alzheimer's research & therapy · 2024Article
- Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024Review
- Transcranial Magnetic Stimulation Across the Lifespan: Impact of Developmental and Degenerative Processes.Biological psychiatry · 2024Review
- Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIn the last decade, non-invasive blood-based and neurophysiological biomarkers have shown great potential for the discrimination of several neurodegenerative disorders. However, in the clinical workup of patients with cognitive impairment, it will be highly unlikely that any biomarker will achieve the highest potential predictive accuracy on its own, owing to the multifactorial nature of Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD).
methodsIn this retrospective study, performed on 202 participants, we analysed plasma neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and tau phosphorylated at amino acid 181 (p-Tau
resultsWe observed significant differences in plasma NfL, GFAP, and p-Tau
conclusionsThe combined assessment of plasma and neurophysiological measures may greatly improve the differential diagnosis of AD and FTLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.